# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
•MediBeacon®Transdermal GFR System (TGFR) is a first-in-kind product for point of care assessment of kidney function in patient...
Innovate (NYSE:VATE) reported quarterly losses of $(1.67) per share. This is a 267 percent decrease over earnings of $1.00 per ...